Trial Profile
A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 02 Nov 2020 Protocol was amended after 30 patients were enrolled to restrict the number of prior lines to 0-2 to include a less heavily pretreated population.
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.